TAMOXIFEN CITRATE

/static/temp/default.svg

Search structure


Trade Names	NOLVADEX SOLTAMOX TAMOXIFEN CITRATE
Synonyms	Emblon Fentamox 10 Fentamox 20 I.C.I.46474 CITRATE ICI 46,474 ICI-46474 Kentadex Kessar Kessar 10 Kessar 20 NSC-180973 NSC-757345 Noltam Nolvadex Nolvadex d Nolvadex fte Nourytam Oestrifen-10 Oestrifen-20 Oestrifen-40 Soltamox Tamofen Tamofene Tamoxifen citrate Tamoxifeni citras Tomaxasta Zemide Zitazonium Zynoplex
Status
Molecule Category	Salt-form
UNII	7FRV7310N6
EPA CompTox	DTXSID8021301
Parent Compound:	TAMOXIFEN


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	FQZYTYWMLGAPFJ-OQKDUQJOSA-N
Smiles	CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O
InChI	InChI=1S/C26H29NO.C6H8O7/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,4,19-20H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C32H37NO8
Molecular Weight	563.65
AlogP	6.0
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	8.0
Polar Surface Area	12.47
Molecular species	BASE
Aromatic Rings	3.0
Heavy Atoms	28.0

Bioactivity

Mechanism of Action	Action	Reference
Estrogen receptor alpha modulator	MODULATOR	PubMed DailyMed Wikipedia


Protein: Estrogen receptor alpha Description: Estrogen receptor Organism : Homo sapiens P03372 ENSG00000091831

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group A Nuclear hormone receptor subfamily 3 group A member 1	-	1700	-	-	-
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group A Nuclear hormone receptor subfamily 3 group A member 2	-	5	-	-	-
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	109

Assay Description	Organism	Bioactivity	Reference
Antiestrogenic activity in female Rattus norvegicus Wistar (rat) assessed as decrease in estradiol benzoate-induced uterine weight at 25 mg/kg, sc QD for 3 days relative to control	Rattus norvegicus	62.8 %
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	Cricetulus griseus	80.91 %
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	Cricetulus griseus	108.56 %
Inhibition of 17-beta estradiol-induced cell proliferation in human MCF7 cells incubated for 6 days by acid red-52 staining based assay	Homo sapiens	796.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	32.46 %
Antagonist activity at human full-length ERbeta expressed in non-human mammalian expression system assessed as inhibition of 17beta-estradiol-induced response measured after 22 to 24 hrs by luciferase reporter gene assay	Homo sapiens	5.0 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	29.24 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	1.07 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	1.07 %

Cross References

Resources	Reference
ChEBI	9397
ChEMBL	CHEMBL786
FDA SRS	7FRV7310N6
Guide to Pharmacology	1016
KEGG	C07108
PDB	CTX
PubChem	2733525
SureChEMBL	SCHEMBL6365
ZINC	ZINC01530689

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).